{
    "id": 23208,
    "fullName": "PIK3CA E726K",
    "impact": "missense",
    "proteinEffect": "gain of function - predicted",
    "geneVariantDescriptions": [
        {
            "description": "PIK3CA E726K does not lie within any known functional domains of the Pik3ca protein (UniProt.org). E726K has not been biochemically characterized, but is predicted to confer a gain of function on the Pik3ca protein as demonstrated by increased transformation in cell culture (PMID: 29533785).",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 11238,
                    "pubMedId": 29533785,
                    "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 5290,
        "geneSymbol": "PIK3CA",
        "terms": [
            "PIK3CA",
            "CLAPO",
            "CLOVE",
            "CWS5",
            "MCAP",
            "MCM",
            "MCMTC",
            "p110-alpha",
            "PI3K",
            "PI3K-alpha"
        ]
    },
    "variant": "E726K",
    "createDate": "06/14/2016",
    "updateDate": "04/29/2018",
    "referenceTranscriptCoordinates": {
        "id": 171765,
        "transcript": "NM_006218",
        "gDna": "chr3:g.179221146G>A",
        "cDna": "c.2176G>A",
        "protein": "p.E726K",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 9703,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib trial, an estrogen-receptor positive breast cancer patient harboring PIK3CA mutations, E78K, D939G, and E726K, demonstrated progressive disease when treated with a combination of Femara (letrozole) and Alpelisib (BYL719) (PMID: 27126994).",
            "molecularProfile": {
                "id": 26992,
                "profileName": "PIK3CA E78K PIK3CA E726K PIK3CA D939G"
            },
            "therapy": {
                "id": 1553,
                "therapyName": "Alpelisib + Letrozole",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 7484,
                    "pubMedId": 27126994,
                    "title": "A Phase Ib Study of Alpelisib (BYL719), a PI3K\u03b1-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27126994"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19938,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, breast epithelial cells expressing PIK3CA E545K and PIK3CA E726K in cis demonstrated increased sensitivity to growth inhibition by Piqray (Alpelisib) treatment compared to cells expressing individual PIK3CA mutations in culture (PMID: 31699932).",
            "molecularProfile": {
                "id": 34732,
                "profileName": "PIK3CA E545K PIK3CA E726K"
            },
            "therapy": {
                "id": 691,
                "therapyName": "Alpelisib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17631,
                    "pubMedId": 31699932,
                    "title": "Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3K\u03b1 inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31699932"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19946,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, breast epithelial cells expressing PIK3CA E545K and PIK3CA E726K in cis demonstrated increased sensitivity to growth inhibition by Afinitor (everolimus) treatment compared to cells expressing individual PIK3CA mutations in culture (PMID: 31699932).",
            "molecularProfile": {
                "id": 34732,
                "profileName": "PIK3CA E545K PIK3CA E726K"
            },
            "therapy": {
                "id": 735,
                "therapyName": "Everolimus",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17631,
                    "pubMedId": 31699932,
                    "title": "Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3K\u03b1 inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31699932"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19942,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, breast epithelial cells expressing PIK3CA E545K and PIK3CA E726K in cis demonstrated increased sensitivity to growth inhibition by GDC-0077 treatment compared to cells expressing individual PIK3CA mutations in culture (PMID: 31699932).",
            "molecularProfile": {
                "id": 34732,
                "profileName": "PIK3CA E545K PIK3CA E726K"
            },
            "therapy": {
                "id": 5181,
                "therapyName": "GDC-0077",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17631,
                    "pubMedId": 31699932,
                    "title": "Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3K\u03b1 inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31699932"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19949,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, breast epithelial cells expressing PIK3CA E726K and PIK3CA H1047R in cis demonstrated increased sensitivity to growth inhibition by Afinitor (everolimus) treatment compared to cells expressing individual PIK3CA mutations in culture (PMID: 31699932).",
            "molecularProfile": {
                "id": 34733,
                "profileName": "PIK3CA E726K PIK3CA H1047R"
            },
            "therapy": {
                "id": 735,
                "therapyName": "Everolimus",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17631,
                    "pubMedId": 31699932,
                    "title": "Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3K\u03b1 inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31699932"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19941,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, breast epithelial cells expressing PIK3CA E726 and PIK3CA H1047R in cis demonstrated increased sensitivity to growth inhibition by Piqray (Alpelisib) treatment compared to cells expressing individual PIK3CA mutations in culture, while cells expressing PIK3CA E726 and PIK3CA H1047R in trans did not (PMID: 31699932).",
            "molecularProfile": {
                "id": 34733,
                "profileName": "PIK3CA E726K PIK3CA H1047R"
            },
            "therapy": {
                "id": 691,
                "therapyName": "Alpelisib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17631,
                    "pubMedId": 31699932,
                    "title": "Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3K\u03b1 inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31699932"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19945,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, breast epithelial cells expressing PIK3CA E726K and PIK3CA H1047R in cis demonstrated increased sensitivity to growth inhibition by GDC-0077 treatment compared to cells expressing individual PIK3CA mutations in culture (PMID: 31699932).",
            "molecularProfile": {
                "id": 34733,
                "profileName": "PIK3CA E726K PIK3CA H1047R"
            },
            "therapy": {
                "id": 5181,
                "therapyName": "GDC-0077",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17631,
                    "pubMedId": 31699932,
                    "title": "Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3K\u03b1 inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31699932"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 23887,
            "profileName": "PIK3CA E726K",
            "profileTreatmentApproaches": [
                {
                    "id": 18163,
                    "name": "mTOR Inhibitor",
                    "profileName": "PIK3CA E726K"
                },
                {
                    "id": 18161,
                    "name": "mTORC2 Inhibitor",
                    "profileName": "PIK3CA E726K"
                },
                {
                    "id": 18160,
                    "name": "PIK3CA inhibitor",
                    "profileName": "PIK3CA E726K"
                },
                {
                    "id": 18166,
                    "name": "PI3K Inhibitor (Pan)",
                    "profileName": "PIK3CA E726K"
                },
                {
                    "id": 18162,
                    "name": "Akt Inhibitor (Pan)",
                    "profileName": "PIK3CA E726K"
                },
                {
                    "id": 18159,
                    "name": "Akt2 Inhibitor",
                    "profileName": "PIK3CA E726K"
                },
                {
                    "id": 18165,
                    "name": "mTORC1 Inhibitor",
                    "profileName": "PIK3CA E726K"
                },
                {
                    "id": 18164,
                    "name": "Akt1 Inhibitor",
                    "profileName": "PIK3CA E726K"
                }
            ]
        },
        {
            "id": 26992,
            "profileName": "PIK3CA E78K PIK3CA E726K PIK3CA D939G",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34732,
            "profileName": "PIK3CA E545K PIK3CA E726K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34733,
            "profileName": "PIK3CA E726K PIK3CA H1047R",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 171765,
            "transcript": "NM_006218",
            "gDna": "chr3:g.179221146G>A",
            "cDna": "c.2176G>A",
            "protein": "p.E726K",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 171764,
            "transcript": "XM_006713658",
            "gDna": "chr3:g.179221146G>A",
            "cDna": "c.2176G>A",
            "protein": "p.E726K",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 171766,
            "transcript": "XM_011512894",
            "gDna": "chr3:g.179221146G>A",
            "cDna": "c.2176G>A",
            "protein": "p.E726K",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}